Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test

Acta Ophthalmologica Scandinavica

Volumn 80, Issue 3, 2002, Pages 272-276

  Stewart, William C ^a,b   Stewart, Jeanette A ^a   Crockett, Steve ^c   Kubilus, Christine ^d   Brown, Alison ^d   Shams, Naveed ^d  

^a University of South Carolina   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DATA Inc   (United States)

^d Novartis Ophthalmics Inc   (United States)

Author keywords

Cardiovascular effect; Docosanoid; Glaucoma; Heart rate; Ocular hypertension; Timolol; Treadmill test; Unoprostone

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO; TIMOLOL; UNCLASSIFIED DRUG; UNOPROSTONE; UNOPROSTONE ISOPROPYL ESTER;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRY EYE; EYE IRRITATION; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREADMILL EXERCISE; VISUAL IMPAIRMENT; VOLUNTEER;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CROSS-OVER STUDIES; DINOPROST; DOUBLE-BLIND METHOD; DRUG EVALUATION; EXERCISE; EXERCISE TEST; FEMALE; HEART RATE; HUMANS; MALE; OPHTHALMIC SOLUTIONS; SAFETY; TIMOLOL;

EID: 0036087230     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0420.2002.800308.x     Document Type: Article

References (16)

1. Safety of unoprostone 0.15% as mono- or adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension
2. Studies on receptor binding and signal transduction pathways of unoprostone isopropyl
3. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men
4. Effect of labetalol on exercise tolerance and double product on mild to moderate essential hypertension
5. Pharmacological characterization of prostaglandin-related ocular hypotensive agents
6. Multiple Comparison Procedures
7. Pharmacological therapy for glaucoma: A review
8. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs
9. Steady-state fluctuation and variability of betaxolol and atenolol plasma levels
10. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine
11. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 Month data
12. FP-receptor mediated trophic effects of prostanoids in rat ventricular cardiomyocytes
13. New and current therapy for glaucoma
14. Systemic side effects of topical beta-blockers
15. Systemic beta-blockade with once daily Betimol or Timoptic-XE both given once daily
16. Exercise testing and training with beta-adrenergic blockade: Role of the drug washout period in 'unmasking' a training effect